As genomic alterations associated with CH can overlap with driver mutations found in tumour DNA, CH variants identified on plasma cell-free DNA testing can be erroneously classified as tumour-derived alterations, leading to inappropriate selection of therapy [67]. The gene discussed is C4B; the disease is neoplasm.